Aibotics, Inc. (AIBT) Cash & Equivalents (2018 - 2026)

Aibotics (AIBT) has 9 years of Cash & Equivalents data on file, last reported at $288858.0 in Q1 2026.

• Quarterly Cash & Equivalents rose 84.29% year-over-year to $288858.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $288858.0 (up 84.29% YoY) and the FY2025 annual result came in at $255940.0, up 38.27% from the prior year.
• Cash & Equivalents grew to $288858.0 in Q1 2026, from $255940.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 million in Q1 2022 to a low of $156737.0 in Q1 2025.
• A 5-year average of $388437.4 and a median of $288858.0 in 2026 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 1338.67% — and 2023, when it sank 75.92%.
• Tracing AIBT's Cash & Equivalents over 5 years: stood at $385899.0 in 2022, then declined by 27.67% to $279134.0 in 2023, then sank by 33.69% to $185097.0 in 2024, then soared by 38.27% to $255940.0 in 2025, then rose by 12.86% to $288858.0 in 2026.
• The last three Cash & Equivalents figures came in at $288858.0 (Q1 2026), $255940.0 (Q4 2025), and $230470.0 (Q3 2025), per Business Quant data.